Pyrrole-based inhibitors of RND-type efflux pumps reverse antibiotic resistance and display anti-virulence potential
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1012121 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Nisha Mahey und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology & Antimicrobial Research Laboratory, CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh, India. Hauptthemen laut MEDLINE: Escherichia coli, Escherichia coli Proteins. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Efflux pumps of the resistance-nodulation-cell division (RND) superfamily, particularly the AcrAB-TolC, and MexAB-OprM, besides mediating intrinsic and acquired resistance, also intervene in bacterial pathogenicity. Inhibitors of such pumps could restore the activities of antibiotics and curb bacterial virulence. Here, we identify pyrrole-based compounds that boost antibiotic activity in Escherichia coli and Pseudomonas aeruginosa by inhibiting their archetype RND transporters. Molecular docking and biophysical studies revealed that the EPIs bind to AcrB. The identified efflux pump inhibitors (EPIs) inhibit the efflux of fluorescent probes, attenuate persister formation, extend post-antibiotic effect, and diminish resistant mutant development. The bacterial membranes remained intact upon exposure to the EPIs. EPIs also possess an anti-pathogenic potential and attenuate P . aeruginosa virulence in vivo . The intracellular invasion of E . coli and P . aeruginosa inside the macrophages was hampered upon treatment with the lead EPI. The excellent efficacy of the EPI-antibiotic combination was evidenced in animal lung infection and sepsis protection models. These findings indicate that EPIs discovered herein with negligible toxicity are potential antibiotic adjuvants to address life-threatening Gram-negative bacterial infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Microbiology & Antimicrobial Research Laboratory, CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh, India.
- Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
- Department of Natural Products, National Institute of Pharmaceutical Education and Research, Mohali, India.
- Structural Biology Laboratory, CSIR-Institute of Microbial Technology, Chandigarh, India.
ORCID-Profile: Hemraj Nandanwar
Förderung
- BLRD VA
- Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Mahey, N., Tambat, R., Kalia, R., Ingavale, R., Kodesia, A., Chandal, N., Kapoor, S., Verma, D. K., Thakur, K. G., Jachak, S., & Nandanwar, H. (2024). Pyrrole-based inhibitors of RND-type efflux pumps reverse antibiotic resistance and display anti-virulence potential. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012121
Vancouver
Mahey N, Tambat R, Kalia R, Ingavale R, Kodesia A, Chandal N, et al. Pyrrole-based inhibitors of RND-type efflux pumps reverse antibiotic resistance and display anti-virulence potential. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012121
BibTeX
@article{Mahey2024,
author = {Mahey, Nisha and Tambat, Rushikesh and Kalia, Ritu and Ingavale, Rajnita and Kodesia, Akriti and Chandal, Nishtha and Kapoor, Srajan and Verma, Dipesh Kumar and Thakur, Krishan Gopal and Jachak, Sanjay and Nandanwar, Hemraj},
title = {Pyrrole-based inhibitors of RND-type efflux pumps reverse antibiotic resistance and display anti-virulence potential},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1012121}
}
EUVIMED